State Key Laboratory for Infectious Diseases Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
State Key Laboratory for Infectious Diseases Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; Immunology Department, Changzhi Medical College, Changzhi 046000, Shanxi, China.
Biomed Environ Sci. 2018 Apr;31(4):290-299. doi: 10.3967/bes2018.037.
Macrolide susceptibility and drug resistance mechanisms of clinical non-tuberculous mycobacteria (NTM) isolates were preliminarily investigated for more accurate diagnosis and treatment of the infection in China.
Four macrolides, including clarithromycin (CLAR), azithromycin (AZM), roxithromycin (ROX), and erythromycin (ERY), were used to test the drug susceptibility of 310 clinical NTM isolates from six provinces of China with the broth microdilution method. Two resistance mechanisms, 23S rRNA and erm, were analyzed with nucleotide sequence analysis.
Varied effectiveness of macrolides and species-specific resistance patterns were observed. Most Mycobacterium abscessus subsp. massiliense were susceptible and all M. fortuitum were highly resistant to macrolides. All the drugs, except for erythromycin, exhibited excellent activities against slow-growing mycobacteria, and drug resistance rates were below 22.2%. Only four highly resistant strains harbored 2,058/2,059 substitutions on rrl and none of other mutations were related to macrolide resistance. G2191A and T2221C on rrl were specific for the M. abscessus complex (MABC). Seven sites, G2140A, G2210C, C2217G, T2238C, T2322C, T2404C, and A2406G, were specifically carried by M. avium and M. intracellulare. Three sites, A2192G, T2358G, and A2636G, were observed only in M. fortuitum and one site G2152A was specific for M. gordonae. The genes erm(39) and erm(41) were detected in M. fortuitum and M. abscessus and inducible resistance was observed in relevant sequevar.
The susceptibility profile of macrolides against NTM was demonstrated. The well-known macrolide resistance mechanisms, 23S rRNA and erm, failed to account for all resistant NTM isolates, and further studies are warranted to investigate macrolide resistance mechanisms in various NTM species.
初步研究临床非结核分枝杆菌(NTM)分离株对大环内酯类药物的敏感性和耐药机制,以便更准确地诊断和治疗中国的感染。
采用肉汤微量稀释法检测来自中国 6 个省的 310 株临床 NTM 分离株对 4 种大环内酯类药物(克拉霉素、阿奇霉素、罗红霉素和红霉素)的药敏性。采用核苷酸序列分析检测 23S rRNA 和 erm 两种耐药机制。
观察到大环内酯类药物的有效性和种特异性耐药模式存在差异。大多数脓肿分枝杆菌亚种和所有偶然分枝杆菌对大环内酯类药物均高度敏感。除红霉素外,所有药物对缓慢生长分枝杆菌均具有优异的活性,耐药率低于 22.2%。只有 4 株高度耐药株在 rrl 上存在 2058/2059 位取代,没有其他突变与大环内酯类耐药相关。rrl 上的 G2191A 和 T2221C 是脓肿分枝杆菌复合体(MABC)的特异性。G2140A、G2210C、C2217G、T2238C、T2322C、T2404C 和 A2406G 等 7 个位点仅存在于鸟分枝杆菌和胞内分枝杆菌中。A2192G、T2358G 和 A2636G 仅存在于偶发分枝杆菌中,而 G2152A 仅存在于戈登分枝杆菌中。在偶发分枝杆菌和脓肿分枝杆菌中检测到 erm(39)和 erm(41)基因,并观察到相关序列的诱导耐药性。
本研究展示了大环内酯类药物对 NTM 的药敏谱。众所周知的大环内酯类耐药机制 23S rRNA 和 erm 无法解释所有耐药的 NTM 分离株,需要进一步研究以探讨各种 NTM 物种中的大环内酯类耐药机制。